Teva's (TEVA +0.4%) Copaxone multiple sclerosis drug performed well vs. a placebo in a Phase III trial that assessed its effectiveness under a new dosage regime of 40mg three times a week rather than the usual 20mg a day schedule
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.